Stafford v. Rite Aid Corporation

District Court, S.D. California·Decided July 30, 2020·No. 3:17-cv-01340·Unknown

Opinion

1 2 3 4 5 6 7 10 11 BRYON STAFFORD, Individually Lead Case No.: 3:17-cv-01340-AJB-JLB and on Behalf of All Others (Consolidated with Case No. 3:18-cv- 12 Similarly Situated, 00152-AJB-JLB) 13 Plaintiff, ORDER: 14 v.

15 RITE AID CORPORATION, (1) GRANTING PLAINTIFFS’ Defendant. MOTION TO APPOINT INTERIM 16 CO-LEAD CLASS COUNSEL, (Doc. 17 No. 105);

18 (2) GRANTING EX PARTE MOTION 19 TO STAY PENDING APPEAL, (Doc. No. 183); AND 20

21 (3) STAYING PLAINTIFFS STAFFORD AND JOSTEN’S 22 MATTERS 23 24 Presently pending before the Court are: (1) Bryon Stafford (“Stafford”) and Robert 25 Josten’s (“Josten”) (collectively, “Plaintiffs”) unopposed motion to appoint interim co-lead 26 class counsel. (Doc. No. 105), and (2) Defendant Rite Aid Corporation’s (“Rite Aid”) ex 27 parte motion to stay pending appeal. (Doc. No. 183.) Plaintiff Stafford filed an opposition 28 1 1 to Rite Aid’s ex parte motion. (Doc. No. 185.) For the reasons set forth in detail below, the 2 Court GRANTS (1) Plaintiffs’ unopposed motion to appoint, (2) GRANTS Rite Aid’s ex 3 parte motion, and (3) STAYS Plaintiffs’ matters pending Rite Aid’s appeal. 5 This is a putative class action filed against Rite Aid Corporation and Rite Aid Hdqtrs. 6 Corporation (“Rite Aid HQ”) for an alleged deceptive and unfair pricing scheme involving 7 Rite Aid’s Rx Savings Program. (Third Amended Complaint (“TAC”), Doc. No. 145.) 8 As general background, the overwhelming majority of Rite Aid’s clients are enrolled 9 in either a private or public health care plan that covers some or all medical and 10 pharmaceutical expenses. (Id. ¶ 28.) In almost every one of these plans, the cost of 11 prescription drugs is shared between the third-party payor (“TPPs”) (i.e., the health 12 insurance plan) and the actual user of the drug (i.e., the plan participant). (Id.) When a plan 13 participant fills a prescription at a pharmacy under a third-party health care plan, the plan 14 pays a portion of the cost, and the plan participant pays the remaining portion of the cost 15 directly to the pharmacy as a copayment. (Id.) Because of the cost savings associated with 16 generic drugs as opposed to brand name drugs, TPPs incentivize plan participants to 17 purchase generic drugs by offering a lower price, which in turn, results in a lower 18 copayment. (Id. ¶ 6.) By law, Rite Aid cannot charge a copayment that exceeds its “usual 19 and customary” price, which is generally defined within the pharmaceuticals industry. (Id. 20 ¶ 7.) The process by which financial responsibility between TPPs and plan participants is 21 determined is called “adjudication.” Rite Aid contracts with pharmacy benefit managers 22 (“PBMs”) and TPPs to “adjudicate” the claims of customers for prescription drug coverage. 23 (Doc. No. 78-1 at 7.) The contracts specify Rite Aid’s obligations to the TPP or PBM when 24 submitting claims for prescription coverage at the point of sale, as well as the amount Rite 25 Aid will receive as payment when filling prescriptions. (Id. at 8.) Generally, the TPP or 26 PBM determines the amount of reimbursement according to those contracts as well as the 27 copayment or deductible amount. (Id.) The TPP or PBM then transmits the information 28 2 1 back to Rite Aid, instructing Rite Aid on the amount to collect from the customer. (Id.) 2 Plaintiffs allege Rite Aid overcharges customers for generic prescription drugs by 3 submitting to TPP/PBMs claims for payment at prices that Rite Aid has inflated above its 4 “usual and customary” prices. (TAC ¶ 8.) As a result, customers who purchase generic 5 prescription drugs through third-party plans pay copayments that are significantly higher 6 than Rite Aid’s “usual and customary” prices for those same drugs. (Id.) Central to this 7 scheme, according to Plaintiffs, is the Rx Savings Program. (Id. ¶ 9.) 8 The Rx Savings Program allows cash-paying customers (customers who pay for 9 prescription drugs without using insurance) to buy the most commonly prescribed generic 10 drugs at significantly discounted prices. (Id.) The Rx Savings Program prices are often 11 significantly lower than the prices Rite Aid reports to health insurance companies as Rite 12 Aid’s “usual and customary” prices. (Id.) Plaintiffs claim Rite Aid was required by law to 13 report to the TPP/PBMs the Rx Savings Program prices as Rite Aid’s “usual and 14 customary” prices for the prescription generic drugs. (Id. ¶ 11.) The failure to do so 15 distorted the overall prescription calculations, resulting in higher copayments to customers. 16 (Id.) Based on this alleged scheme, Plaintiff Stafford brings claims against Rite Aid for: 17 (1) negligent misrepresentation, (2) unjust enrichment, (3) violation of the Consumer Legal 18 Remedies Act (“CLRA”), (4) and violation of the California Unfair Competition Law 19 (“UCL”). Plaintiff Josten brings similar claims, and asserts an additional claim for 20 declaratory and injunctive relief. (Doc. No. 146 at 42.) 22 Plaintiff Stafford’s Complaint was first filed in June 30, 2017. (Doc. No. 1.) A First 23 Amended Complaint was filed on July 28, 2017, (Doc. No. 18), and Rite Aid moved to 24 dismiss for failure to state a claim. (Doc. No. 19.) The Court granted Rite Aid’s motion to 25 dismiss with leave to amend. Plaintiff Stafford filed a Second Amended Complaint on 26 January 9, 2018. (Doc. No. 30.) On January 23, 2018, another plaintiff, Plaintiff Josten, 27 instituted a substantially similar action against Rite Aid. (See Case No. 18-cv-00152-AJB- 28 3 1 JLB, Doc. No. 1.) Plaintiff Stafford and Josten’s actions were consolidated by the Court on 2 October 24, 2019. (Doc. No. 101.) 3 On January 23, 2018, Rite Aid filed its second motion to dismiss Plaintiff Stafford’s 4 Second Amended Complaint for failure to state a claim. (Doc. No. 32-1.) On September 5 28, 2018, the Court denied Rite Aid’s motion to dismiss, holding that Plaintiff Stafford 6 plausibly stated a claim on all four causes of action. (Id.) On June 17, 2019, Ride Aid then 7 filed a motion to compel arbitration. (Doc. No. 78.) On February 25, 2020, the Court denied 8 the motion to compel arbitration, holding Rite Aid failed to show equitable estoppel should 9 apply, thus Rite Aid did not have a right to arbitrate. (Doc. No. 134.) The Court concluded 10 that in any event, Rite Aid waived any rights to compel arbitration by filing multiple 11 motions to dismiss on the merits. (Id.) On March 24, 2020, Rite Aid filed a notice of appeal 12 of the Court’s order denying the motion to compel Stafford to arbitration. (Doc. No. 148.) 13 Rite Aid similarly filed two motions to dismiss in Plaintiff Josten’s case before filing 14 a motion to compel arbitration, which is currently pending before the Court. (Case No. 18- 15 cv-00152-AJB-JLB, Doc. Nos. 15, 28.) 16 On March 3, 2020, before Rite Aid filed the notice of appeal, the parties filed a joint 17 motion for leave to amend both Stafford’s and Josten’s Complaints to add party defendant 18 Rite Aid HQ, which was granted by the Court. (Doc. No. 136.) Rite Aid HQ also filed 19 motions to compel Stafford and Josten to arbitration, which currently pending before the 20 Court, along with Rite Aid’s motion to compel Josten to arbitration. (Doc. Nos. 114, 163, 21 166.) 22 On June 10, 2020, Rite Aid filed an ex parte motion to stay pending resolution of its 23 appeal to the Ninth Circuit. (Doc. No. 183.) Stafford opposed. (Doc. No. 185.) This order 24 follows. 25 III. PLAINTIFFS’ MOTION TO APPOINT INTERIM CO-LEAD CLASS 27 First, Stafford and Josten seek an order appointing Robbins Geller Rudman & Dowd 28 4 1 LLP (“Robbins Geller”) and Scott+Scott Attorneys at Law LLP (“Scott+Scott”) as Interim 2 Co-Lead Class Counsel. (Doc. No. 105.) Rite Aid filed a non-opposition to the motion. 3 (Doc. No. 108.) 4 “The court may designate interim counsel to act on behalf of a putative class before 5 determining whether to certify the action as a class action.” Fed. R. Civ. P.

Free access — add to your briefcase to read the full text and ask questions with AI

Stafford v. Rite Aid Corporation, (S.D. Cal. 2020).

Stafford v. Rite Aid Corporation (Stafford v. Rite Aid Corporation) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Landis v. North American Co.
299 U.S. 248 (Supreme Court, 1936)
Hilton v. Braunskill
481 U.S. 770 (Supreme Court, 1987)
Clinton v. Jones
520 U.S. 681 (Supreme Court, 1997)
Nken v. Holder
556 U.S. 418 (Supreme Court, 2009)
Leiva-Perez v. Holder
640 F.3d 962 (Ninth Circuit, 2011)
O'Brien v. O'Laughlin
557 U.S. 1301 (Supreme Court, 2009)
Lockyer v. Mirant Corp.
398 F.3d 1098 (Ninth Circuit, 2005)
Sanford v. Memberworks, Inc.
483 F.3d 956 (Ninth Circuit, 2007)
In re Kentucky Elkhorn Coal Corp.
19 F.2d 264 (E.D. Kentucky, 1926)
Alascom, Inc. v. ITT North Electric Co.
727 F.2d 1419 (Ninth Circuit, 1984)
Britton v. Co-Op Banking Group
916 F.2d 1405 (Ninth Circuit, 1990)